European Commission approves JASCAYD, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
Not intended for UK and US audiences*JASCAYD (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, deliver
